The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L04 | Immunosuppressants | |
3
|
L04A | Immunosuppressants | |
4
|
L04AB | Tumor necrosis factor alpha (TNF-α) inhibitors | |
5
|
L04AB02 | Infliximab |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| PAREN | Parenteral | 3.75 mg |
| Active Ingredient |
|---|
|
Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFβ). |
| Document | Type | Information Source | |
|---|---|---|---|
| AVSOLA Powder for solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| FLIXABI Powder for concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| INFLECTRA Powder for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| RENFLEXIS Powder for solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| ZESSLY Powder for concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.